A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
for Alzheimer's Disease
11 locations incl. Irvine
Sponsor: AbbVie
Sex: All·Age: 50 - 90
Code: NCT07599670·Phase 1, Phase 2·Recruiting·Listed May 2026